Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingPhase 4interventionalRules rewrite

Phase 4: testing Atomoxetine-oxybutynin for Obstructive Sleep Apnea (OSA)

Researchers want to identify which treatments for obstructive sleep apnea (OSA) work best and are easiest for patients to use consistently. Eligible you would be randomly assigned one of three OSA treatments: traditional PAP therapy, a dental device, or a combination of two FDA-approved medications (atomoxetine and oxybutynin) that are currently approved for other conditions.

Official registry: https://clinicaltrials.gov/study/NCT07679282 · Sairam Parthasarathy · enrollment listed as 2,400

What this phase means

Phase 4: the treatment is already approved. This study asks new questions — longer-term effects, other diseases, or how it compares in everyday care.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Positive airway pressure (PAP) therapy, Sleep dental device, or Atomoxetine-oxybutynin. The registry lists allocation as randomized. Researchers want to identify which treatments for obstructive sleep apnea (OSA) work best and are easiest for patients to use consistently.

They plan to enroll about 2,400 people at 4 sites. Taking part typically means taking a study drug (or dummy pill), using or being fitted with a device plus check-ins.

Official title (unrewritten)

Comparative Effectiveness of Positive Airway Pressure Therapy, Dental Device, and Atomoxetine-Oxybutynin for Sleep Apnea: the ADAPT-OSA Study

Interventions: Positive airway pressure (PAP) therapy, Sleep dental device, Atomoxetine-oxybutynin

Primary outcome (registry wording): Health-related quality of life

Who it is for (from inclusion criteria)

  • Ages 18 Years to any
  • Obstructive sleep apnea (AHI \>/= 5 per hour), diagnosed in the past 6 months
  • Two or more of the following symptoms: snoring, fragmented sleep, witnessed apneas, or daytime sleepiness
  • Willingness/ability to use any of the 3 treatments for OSA (PAP, dental device, or atomoxetine-oxybutynin)
  • Health insurance of any type

Public study contact (from the registry)

Heidi Erickson, BSN, RN

1-520-626-5287

herickso@arizona.edu

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

4 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBethesda, Maryland
Development of a Wearable Point of Care Monitoring Device for Pediatric Obstructive Sleep Apnea

Background: Obstructive sleep apnea (OSA) occurs when the blockage of the airway causes a person to stop breathing involuntarily for 10 seconds or more throughout the night during sleep. Pediatric OSA can be especially concerning and can have long-term effects.

NCT05052216 · Official ClinicalTrials.gov record · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

RecruitingNot a traditional drug phaseSan Diego, California
Not a traditional drug phase: Positive Airway Pressure Device for Post Traumatic Stress Disorder

Substance use disorder (SUD) and posttraumatic stress disorder (PTSD) frequently co-occur and having both disorders is associated with greater psychological and functional impairment than having either disorder alone. This is especially true in residential settings where both disorders are more severe than outpatient settings.

NCT05156112 · Official ClinicalTrials.gov record · VA Office of Research and Development

RecruitingNot a traditional drug phaseBeijing
Not a traditional drug phase: Level III portable sleep study for Sleep Apnea

The investigators propose a prospective, watch-and-measure (no experimental treatment required) study to determine the impact of OSA and associated physiological parameters on clinical outcomes in patients with pulmonary hypertension. The prevalence, phenotypes, and predictors of OSA in the setting of pulmonary hypertension will also be investigated.

NCT05595200 · Official ClinicalTrials.gov record · Chinese Pulmonary Vascular Disease Research Group

FAQ about this NCT record

Is NCT07679282 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07679282?

Phase 4. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07679282?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary